TuHURA Biosciences Extends Cash Runway to Late 2028, Secures $50M Credit Facility & Begins ATM Sales

summarizeSummary

TuHURA Biosciences reported Q1 2026 results, extending its cash runway to late 2028 through a new $50M credit facility and initial ATM sales, mitigating prior going concern concerns.

check_boxKey Events

• Cash Runway Extended

  The company expects its existing capital resources, including the new $50 million revolving credit facility, to fund planned operations into the end of 2028. This significantly extends the runway and addresses the prior going concern warning issued on March 31, 2026.

• Q1 2026 Financial Results

  TuHURA Biosciences reported a net loss of $7.5 million for the three months ended March 31, 2026, compared to a $6.7 million net loss in Q1 2025. Cash and cash equivalents were $6.3 million as of March 31, 2026.

• ATM Program Initiated

  The company began making sales under its At-The-Market (ATM) offering program in April 2026, selling 104,000 shares at a weighted average price of $3.09 per share for gross proceeds of $321,000. The program allows for sales of up to $50 million in common stock.

• $50 Million Credit Facility Details

  The $50 million revolving credit facility from Parkview Holdings One LLC (an affiliate of a >5% stockholder) bears 12% interest. A $5 million commitment fee was paid by issuing 1,878,287 shares of common stock (subject to stockholder approval). No proceeds have been drawn from the facility to date.

auto_awesomeAnalysis

This quarterly report provides a critical update on TuHURA Biosciences' financial stability, extending its cash runway into late 2028. This directly addresses the previous going concern warning by detailing the impact of the recently secured $50 million revolving credit facility and initial sales under the $50 million At-The-Market (ATM) program. While the company continues to incur losses and faces significant potential dilution from warrants and future equity issuances, the successful securing of long-term funding is a major de-risking event for its operations and clinical trials.